Leiper, J. M. (2005) The DDAH-ADMA-NOS pathway. Therapeutic Drug Monitoring, 27(6), pp. 744-746. (doi: 10.1097/01.ftd.0000179849.42395.11) (PMID:16404814)
Full text not currently available from Enlighten.
Abstract
An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS),particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.
| Item Type: | Articles |
|---|---|
| Additional Information: | Proceedings of the 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, April 23-28, 2005 |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Leiper, Professor James |
| Authors: | Leiper, J. M. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Therapeutic Drug Monitoring |
| Publisher: | Lippincott, Williams & Wilkins |
| ISSN: | 0163-4356 |
| ISSN (Online): | 1536-3694 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details